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We compared the performance of the 3D-Gene® mutation assay (3D-Gene® KRAS mutation assay kit) with the
Scorpion-ARMS (therascreen® KRAS RGQ PCR Kit) and Luminex (MEBGEN™ KRAS kit) assays for the detection of KRAS
mutations in formalin-fixed, paraffin-embedded tissue samples from 150 patients diagnosed with colorectal cancer.
DNA was extracted from the paraffin-embedded tissue samples with or without macrodissection under hematoxylin
and eosin staining and the KRAS mutation status was independently determined using these assays. Discordant
results were re-analyzed by Sanger sequencing. Mutation detection analysis was successfully performed in all
150 specimens using the 3D-Gene® mutation assay without an invalid case. The concordance rate between
the 3D-Gene® mutation assay and Scorpion-ARMS or Luminex was 98.7% (148/150). KRAS mutations were detected
at a frequency of 35.3% (53/150) in colorectal cancer specimens. Three discrepant cases were found between the three
assays. Overall, our results demonstrate a high concordance rate of between the 3D-Gene® mutation assay and the two
existing in-vitro diagnostics kits. All three assays proved to be validated methods for detecting clinically significant KRAS
mutations in paraffin-embedded tissue samples.
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Several studies have shown that cetuximab and panitu-
mumab do not improve progression-free or overall
survival for advanced colorectal cancer patients with
mutated KRAS (Karapetis et al. 2008; Amado et al.
2008; De Roock et al. 2008; Lièvre et al. 2006, 2008).
KRAS is a GTP binding protein with a molecular weight
of 21 kDa. KRAS is activated by GTP binding triggered by
upstream signals such as EGFR. The KRAS gene is located
on chromosome 12 and consists of 4 exons and 3 introns.
Single base mutations of KRAS genes decrease GTPase ac-
tivity and leads to constitutive activation of KRAS. The
frequency of KRAS mutations is 34.6% in colorectal
cancer, according to the COSMIC (Catalogue of Somatic
Mutation in Cancer) database. Comparable frequen-
cies have also been reported in population–based studies.* Correspondence: knishio@med.kindai.ac.jp
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in any medium, provided the original work is p(Andreyev et al. 1998; Karapetis et al. 2008). Major muta-
tions of KRAS occur in exon 2 (codons 12 and 13). Two
phase III clinical trials, OPUS and CRYSTAL, have dem-
onstrated that codon 12 and 13 mutations are predictive
for cetuximab activity in combination with FOLFOX or
FOLFIRI, respectively (Bokemeyer et al. 2011; Van Cutsem
et al. 2011). An additional study also demonstrated that
cetuximab combined with first line chemotherapy is ef-
fective for patients with KRAS G13D tumor mutations
(Bokemeyer et al. 2012). A variety of studies have shown
that KRAS mutations influence the response to the anti-
EGFR antibodies cetuximab and panitumumab (Jonker
et al. 2007; Karapetis et al. 2008). Several methods have
been reported for the detection of KRAS mutations in
formalin-fixed paraffin embedded (FFPE) tissues (Gonzalez
de Castro et al. 2012; Chang et al. 2013; Altimari et al.
2013). The Sanger sequencing method is currently the gold
standard (Allegra et al. 2009), however, several KRAS mu-
tation kits have become available for colorectal cancer
patients.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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This technology has been applied for gene expression
profiling and miRNA analysis (Sato et al. 2009; Sudo
et al. 2012). 3D-Gene® microarray has a micro-columnar
structure and uses a bead-agitation technique to achieve
high sensitivity and reproducibility. Toray has established
a new 3D-Gene® assay for the detection of KRAS muta-
tions in tumor tissues using the PCR-rSSO (PCR-reverse
sequence-specific oligonucleotide) method. Both Luminex
and 3D-Gene® assays are based on the PCR-rSSO method.
However, fluorescent beads are detected by flow cytom-
etry in the Luminex assay. On the other hand, the 3D-
Gene® assay utilizes array technology for the detection of
the fluorescent PCR product. In this study, we compared
the clinical performance of the 3D-Gene® mutation assay
with two other assays (Scorpion-ARMS and Luminex)
using FFPE tissue specimens from colorectal cancer pa-
tients (Harlé et al. 2013; Fukushima et al. 2011).Results
Sensitivity of 3D-Gene® KRAS mutation assay
The minimum number of mutant DNA copies that were
reliably detected by the 3D-Gene® assay was 350–700
copies (2.5-5%) as determined by using serially diluted
mutant DNA (G12S) against wild-type DNA of HeLa cells
(15000 copies; 50 ng). The minimum threshold for the
number of mutant DNA copies was 700–1400 (5-10%)
using serially diluted mutant DNA (G13D) against wild-
type DNA of HeLa cells.Study population
One hundred fifty FFPE tissue samples from patients with
colorectal cancer in Kinki University Hospital, Faculty of
Medicine were examined. All of the samples were avail-
able for analysis. The clinical and pathological characteris-








G12A 100% (2/2) 100% (148/148) 100% (150/150)Mutation types of KRAS
KRAS mutations were detected in 53/150 (36.0%), 53/150
(35.3%) and 51/150 (34.0%) cases by 3D-Gene®, Scorpion-
ARMS and Luminex, respectively. (Additional file 1: Table
S2). Mutations were mainly located in codon 12 of KRAS
(40/53, 75.5%). G12V mutations were most frequently ob-
served by all assays (14/53, 26.4%). G13D was detected in
13 cases, but no other mutation in codon 13 was detected.G12C 88.3% (5/6) 99.3% (143/144) 98.6% (148/150)
G12D 100% (13/13) 100% (137/137) 100% (150/150)
G12R 100% (3/3) 100% (147/147) 100% (150/150)
G12S 100% (3/3) 100% (147/147) 100% (150/150)
G12V 100% (14/14) 100% (136/136) 100% (150/150)
G13D 92.3% (12/13) 99.3% (137/138) 99.3% (149/150)
MD: mutation detected, MND: mutation not detected.Invalid test rate
Mutation analysis of exons 12–13 of the KRAS gene
was successfully performed in all 150 specimens (100%)
using the 3D-Gene® mutation assay. No invalid test results
were detected in the two other assays. The invalid test rate
for this study was 0%.Method correlation agreement analysis
We compared the KRAS mutation status across the
three assays: 3D-Gene®, Scorpion-ARMS, and Luminex.
The correlation rates between 3D-Gene® and Scorpion-
ARMS or 3D-Gene® and Luminex were 98.7% (148/150).
The 3D-Gene® assay detected mutant KRAS in two speci-
mens, but were wild-type by the Scorpion-ARMS method.
Two specimens had a discrepant status between 3D-Gene®
and Luminex. The first specimen had a wild-type KRAS
by 3D-Gene® but was mutant by Luminex. Second speci-
men had a mutant KRAS by 3D-Gene® but was wild-type
by Luminex. The concordance of the data from the three
KRAS mutation assays is shown in Additional file 1: Tables
S3 and S4. Only three discordant results between the three
KRAS mutation assays were observed. The site specific
concordant rates are summarized in Tables 1 and 2.
Inconsistencies were found in two mutations (G12C
and G13D), while others remained completely matched.
No statistically significant differences were observed be-
tween the correlations of 3D-Gene® and Scorpion-ARMS
(κ = 0.97, 95% CI 0.86 – 1.000 and 3D-Gene® and Luminex
(κ = 0.97, 95% CI 0.86 – 1.00).
Re-analysis of discordance by Sanger sequencing
Discordant results between the three assays were identi-
fied in three cases. Discordances were observed between
G12C or wild-type KRAS in two cases, and between G13D
and wild-type KRAS in one case. The three discordant
cases were retested using Sanger sequencing on DNA sam-
ples extracted for the 3D-Gene® mutation assay. A mutant
allele was not detected by Sanger sequencing.
Discussion
KRAS mutation testing has become mandatory prior to
the administration of therapy with the anti-EGFR anti-
bodies, cetuximab or panitumumab, for patients with ad-
vanced colorectal cancer. KRAS mutation screening based
on the Scorpion-ARMS KRAS mutation assay (therasc-
reen® KRAS RGQ PCR Kit, Qiagen) has been approved
for in vitro diagnostic use in Japan. A kit using Luminex








G12A 100% (2/2) 100% (148/148) 100% (150/150)
G12C 100% (5/5) 99.3% (144/145) 99.3% (149/150)
G12D 100% (13/13) 100% (137/137) 100% (150/150)
G12R 100% (3/3) 100% (147/147) 100% (150/150)
G12S 100% (3/3) 100% (147/147) 100% (150/150)
G12V 100% (14/14) 100% (136/136) 100% (150/150)
G13D 100% (13/13) 100% (137/137) 100% (150/150)
MD: mutation detected, MND: mutation not detected.
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approved (Fukushima et al. 2011). In this study, we exam-
ined the feasibility and robustness of the 3D-Gene® KRAS
mutation assay kit.
The 3D-Gene® KRAS mutation assay kit is designed to
detect 12 KRAS mutations on codons 12 and 13, and re-
quires 50 ng of DNA. This assay has been validated with
samples comprised of a minimum of 2.5% of tumor DNA.
Thus, experimental assays demonstrate a sensitivity of
2.5%. This sensitivity is comparable to that of other methods
such as Scorpion-ARMS and Luminex. We have demon-
strated that the RFU values for mutant probes were
remarkably lower than the respective cut-off values using
HeLa DNA (wild-type KRAS). Based on this study, we be-
lieve that this assay provides sufficient specificity for the
reliable detection of KRAS mutations. Estimated hands on
time for Scorpion-ARMS, 3D-Gene®, and Luminex are
2.5, 3, and 3.5 hours, respectively. Assay cost for one sam-
ple of 3D-Gene® and Luminex are expected to be lower
than that of Scorpion-ARMS when used under the desig-
nation for “research use only”.
The correlation between the 3D-Gene® KRAS mutation
assay and existing KRAS mutation assays is high. This
result indicates that the 3D-Gene® mutation assay is a
robust assay capable of detecting the most common clin-
ically significant KRAS mutations and is comparable to
existing KRAS mutation assays.
We detected a total of 3 discordant results among 150
(2.0%) cases in this study. The concordance rate was
98.6% between both 3D-Gene® and Scorpion-ARMS (148/
150) and 3D-Gene® and Luminex (148/150). Re-analysis
by Sanger sequencing could not detect any mutations.
However, this might be due to tumor heterogeneity. The
whole process (from DNA extraction to detection) was
performed independently in each of the three assays. Dif-
ferences between the methods of DNA extraction may
have contributed to the discordance among the three
assays.
KRAS mutations in codons 61 and 146, and BRAF,
NRAS, and PI3KCA are also related to resistance to anti-EGFR antibodies (Douillard et al. 2013). Therefore, fur-
ther studies should be carried out to expand the use of
3D-Gene® technology for the detection of “all RAS” and
PI3KCA mutations.Conclusion
In conclusion, our results demonstrate a high concord-
ance rate of between the 3D-Gene® mutation assay and
the two existing in-vitro diagnostics kits. All three assays
proved to be validated methods for detecting clinically
significant KRAS mutations in paraffin-embedded tissue
samples.Methods
Samples
A series of 150 FFPE archived tissues was obtained from
150 Japanese patients with colorectal cancer at Kinki
University Faculty of Medicine (2012–2013). All patients
enrolled in the study provided written informed consent
for the use of resected tissue. This study was approved
by the ethics committee of Kinki University Faculty of
Medicine (Authorization Number: 25–167). All samples
were processed with the 3D-Gene® KRAS mutation,
Scorpion-ARMS and Luminex assays. Three samples
were processed with Sanger sequencing. All 150 samples
were from primary colorectal carcinoma. The patient
characteristics are listed in Additional file 1: Table S1.
Genomic DNA from A549, HCT-116, and HeLa cells
were obtained from ATCC, Takara Bio Inc. (Shiga, Japan)
and New England Biolabs Japan Inc. (Tokyo, Japan),
respectively.Study design
The study design is summarized in Figure 1. Colorectal
cancer samples (150 cases) were selected by a patholo-
gist. All of the hematoxylin and eosin-stained FFPE
slides were examined and the tumor region was marked
by a pathologist at Kinki University Faculty of Medicine.
If the tumor region represented less than 50% on the tis-
sue slice, the tumor regions were macrodissected. DNA
extraction was performed independently for each tissue
slice according to the specific standard operating pro-
cedure for each of the three assays. The 3D-Gene® KRAS
mutation assay (Toray, Tokyo, Japan) was performed at the
Department of Genome Biology, Kinki University (Osaka,
Japan). The Scorpion-ARMS (therascreen® KRAS RGQ
PCR Kit, Qiagen, Tokyo) and Luminex (MEBGEN™ KRAS
gene mutation detection kit, MBL, Nagoya, Japan) assays
were performed at the laboratories of LSI-Medience Co.
(Tokyo, Japan) and SRL Inc. (Hino, Japan), respectively.
All data was compiled and analyzed at Department of
Genome Biology, Kinki University.
Figure 1 Study design. FFPE colorectal cancer tumor specimens (150 cases) were selected and processed using 3D-Gene®, Scorpion-ARMS, and
Luminex. The KRAS mutation status obtained from the three assays was compared.
Figure 2 Assay workflow. Workflow of multiple KRAS mutations by
the 3D-Gene® KRAS mutation assay.
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Paraffin blocks were serially cut at 5 μm thickness. DNA
was purified from the tissue sections using a QIAamp
DNA FFPE Tissue kit (Qiagen, Valencia, CA) according
to the manufacturer’s instructions. DNA quantity was de-
termined by NanoDrop spectrophotometry (NanoDrop
Technologies, Wilmington, DE).
3D-Gene® mutation assay
The 3D-Gene® KRAS mutation assay kit (Toray, Tokyo,
Japan) was used for KRAS mutation profiling. This kit
consists of a DNA chip and PCR reagents. The DNA chip
has probes to detect 12 mutations of KRAS codon 12 and
13 (G12S, G12C, G12R, G12D, G12V, G12A, G13S,
G13C, G13R, G13D, G13V and G13A). The cutoff value
for determining positive mutations was set to 300, but
G12C and G13C were set 385 and 537, respectively. Fifty
nanograms of DNA derived from FFPE tissue was ampli-
fied with the supplied reagent. The PCR product labeled
with fluorescent dye was hybridized onto the DNA chip
surface after denaturation at 95°C for 2 min. Chips were
incubated at 59°C for 30 min under agitation at 1,400 rpm.
After hybridization, the DNA chips were washed and dried
in an ozone-free environment. The fluorescent image was
scanned with the 3D-Gene® Scanner 3000 (Toray Industries,
Inc.). The images obtained from the DNA chip were quanti-
fied by measuring the relative fluorescence unit (RFU) using
3D-Gene® ExTraction software (Toray Industries, Inc.).
This assay determined the mutation to be positive if signal
detected was greater than the cutoff value. The assay
workflow is illustrated in Figure 2. Probe arrangements in
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are shown in Additional file 2: Figures S1 and S2, re-
spectively. Cutoff values were established using KRAS
wild-type and mutant plasmid DNA. We set the average +
5SD (RFU) values obtained from the KRAS wild-type plas-
mid DNA as tentative cutoff value. The values for the
mutation sites were 385, 537, and 300 RFU for G12C,
G13C, and others, respectively. When the 3D-Gene® assay
was performed using codon 12 mutant plasmid DNA, the
minimum measured value among codon 12 mutation was
1009 RFU (G12R), whereas all codon 13 mutation values
were below 300 RFU. When the 3D-Gene® assay was per-
formed using codon 13 mutant plasmid DNA, the mini-
mum measured value among codon 13 mutation was 332
RFU (G13S), whereas all codon 12 mutation values were
below 300 RFU. All assays were performed eight times in-
dependently. Based on these data, we set the cutoff values
for G12C, G13C, and others at 385, 537, and 300 RFU, re-
spectively. Similarly, the cutoff value for wild-type was set
to 300 RFU.
Sensitivity assay
The sensitivity of the 3D-Gene® mutation assay was evalu-
ated by mixing G12S (codon 12) or G13D (codon 13) mu-
tated and wild-type DNA from cell lines (A549 as codon 12
mutated, HCT-116 codon 13 and HeLa cells as wild-type,
respectively) at 100%, 50%, 25%, 5%, 2.5% and 1% ratios.
Scorpion-ARMS
The Scorpion-ARMS assay was analyzed using the ther-
ascreen® KRAS RGQ PCR Kit (Qiagen). The Scorpion-
ARMS assay is a real time-PCR assay that combines the
Amplification Refractory Mutation System (ARMS) and
Scorpions fluorescent primer/probe system. This assay de-
tects G12S, G12C, G12R, G12D, G12V, G12A, and G13D
mutations of KRAS. The sensitivity is 1%. This assay was
performed according to the manufacturer’s guidelines
(Qiagen). Briefly, DNA was isolated from FFPE tissue
samples and the total sample DNA assessed by amplifying
a region of exon 2 from KRAS by PCR. Next, the DNA
samples were tested for the presence or absence of KRAS
mutations by real-time PCR using a Scorpion probe and
primers specific for wild-type and mutant KRAS DNA.
The differences between the mutation assay cycle thresh-
old (Cγ) values were determined. Samples were designated
mutation positive if the δCγ was less than the cutoff δCγ
value.
Luminex
The Luminex assay was analyzed using the MEBGEN™
KRAS kit (MBL, Nagoya, Japan), which is currently ap-
proved for clinical use by the Ministry of Health, Labour
and Welfare of Japan (Fukushima et al. 2011). The Luminex
assay is based on PCR-rSSO method (Itoh et al. 2005); First,50 ng of template DNA collected from FFPE tissue sam-
ples was amplified by PCR using a biotin-labeled primer.
Thereafter, the PCR products and fluorescent Luminex
beads (oligonucleotide probes complementary to wild and
mutant genes bound to the beads) were hybridized and la-
beled with streptavidin–phycoerythrin. Subsequently, the
products were processed by the Luminex assay and the
data collected was then analyzed using UniMAG software
(MBL, Japan). This assay detects G12S, G12C, G12R,
G12D, G12V, G12A, G13S, G13C, G13R, G13D, G13V
and G13A mutations of KRAS.
Sequencing analysis
DNA samples obtained from specimens that were dis-
cordant between three assays were amplified using the fol-
lowing site-specific primers: forward 5′ -AAGGCCTGC
TGAAAATGACTG- 3′, reverse 5′ -GTCCTGCACCAG
TAATATGC- 3′. The purified products were sequenced
using BigDye terminator v3.1 (Applied Biosystems, Foster
City, CA) with ABI 3100 Genetic Analyzer (Applied
Biosystems).
Statistics
Kappa statistics were used to compare the 3D-Gene®
KRAS mutation assay with the Scorpion-ARMS and
Luminex assays.Additional files
Additional file 1: Table S1. Clinicopathological characteristics primary
colorectal cancer patients providing FFPE samples. Table S2. Results of
three different assay. Table S3. Methods correlation between 3D-Gene®
and Scorpion-ARMS. Table S4. Methods correlation between 3D-Gene®
and Luminex.
Additional file 2: Figure S1. Probe arrangements in a microarray cell.
The microarray slide is divided into 8 compartments. Each cell has 13
probes of the KRAS gene, and each probe is represented six times on the
slide. WT: wild-type KRAS, NC: negative control. Figure S2. Representative
scanned image of a microarray. Images shown are representative of
images from three mutant (G12C, G12S and G13D), three wild-type (WT),
one WT control and one negative control (distilled water) samples.Competing interests
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